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Nuclear Magnetic Resonance (NMR). AF-1 and various fragments of AF-1 were cloned in pGEX4t.1 and pGEX6p.1 vectors. To purify proteins, large scale Luria broth cultures were induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) when the O.D. reached 0.6 and incubated in a shaker at 25°C for 6 hours. Cells were harvested and lysed in a lysis buffer (50 mM Tris pH 7.5, 25-250 mM NaCl, DNase, protease inhibitors, glycerol, EGTA, DTT, and sucrose).
Protein lysates were purified using glutathione sepharose beads by incubating overnight at 4°C with gentle rocking and the purified protein was eluted with elution buffer (lysis buffer without DNase) containing 50 mM reduced glutathione. Purified proteins were concentrated using Amicon or GE protein concentrators. In cases where GST needed to be cleaved, precision protease was used to cleave the GST. The proteins were further purified using FPLC (GE AKTA FPLC) with gel filtration (superdex75 10/300 GL) and ion exchange (HiPrep Q FF 16/10) columns. Spectra of compounds alone or in combination with purified protein were recorded using 1 H NMR (Bruker 400MHz) in a total volume of 500 μl with 5 μM protein and 200-500 μM small molecule (dissolved in deuterated DMSO (d6DMSO)) in 20 mM phosphate buffer made up in 100% deuterated water.
NMR data were collected using a Bruker AVANCE III 400MHz NMR spectrometer (Bruker BioSpin Co. Billerica, MA USA) equipped with a BBO 5 mm NMR probe, and TopSpin 3.0 software. 1 H proton NMR and Saturation-Transfer Difference (STD) experiments were acquired using standard pulse sequences in the TopSpin library. Spectral width was set to 16 ppm with H2O 8 and potency studies were performed with a dose range of 1 pM to 10 μM of the molecules, hypotheses-testing proof-of-concept mechanistic studies were performed using 10 μM.
UT-155 and UT-69 effectively antagonize the AR:
All molecules in the library were tested in a battery of experiments, sequentially, to determine their binding to the LBD (using competitive radioligand binding assay) and their antagonistic activity (using transactivation assay). Molecules that bound to the AR-LBD and inhibited the AR activity were tested for their ability to decrease AR expression (using immunoblotting).
A radioligand binding assay with purified GST-AR-LBD and 1 nM 3 
. The Ki for enzalutamide was weaker than previously reported in an assay using 18 F-FDHT as the agonist (2) . While absolute Ki will differ depending on experimental conditions, the rank of relative binding affinity should remain the same.
AR transactivation assays were performed using an AR-responsive reporter and wild type AR, bicalutamide-resistant W742L, and hydroxyflutamide-resistant T878A AR mutants (28,29). UT-155 and UT-69 potently inhibited the R1881-induced wildtype AR transactivation with 6-10-fold higher potency than enzalutamide ( Figure 1B) . While UT-155 and UT-69 antagonized both
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Author Manuscript Published OnlineFirst on October 4, 2017; DOI: 10.1158/0008-5472. wildtype and mutant ARs comparably, enzalutamide was weaker by two fold with the W742L mutant AR relative to the wild type AR ( Figure S1A ).
To test the receptor specificity, cells were transfected as above except that expression plasmids for glucocorticoid receptor (GR), mineralocorticoid receptor (MR), and progesterone receptor (PR) and their corresponding agonists were used. Although UT-155 inhibited GR and MR transactivation, it did so only at ~10 μM ( Figure 1C) . UT-155 did however inhibit the PR transactivation at concentration comparable to that of the AR ( Figure 1C ). The same result was observed with UT-69 (data not shown).
An early event that controls AR-regulated gene expression in response to agonist is the interaction between the N-terminus and the C-terminus of the receptor (N-C interaction) (30) . The N-C interaction depends on agonistic ligands, and does not occur in the presence of antagonists (30).
Moreover, this N-C interaction has been shown to be important for AR interaction with chromatin (31). Given its critical role in AR function, the SARDs were tested for their ability to alter the N-C interaction using a mammalian two hybrid assay. Cells were transfected with Gal-4-DBD-AR-LBD, VP-16-AR-NTD, and Gal-4-RE-LUC, and treated with UT-69 and UT-155. Luciferase assays were performed in the cell lysates 24 hours after treatment. Both UT-155 and UT-69 significantly inhibited the AR N-C interaction with IC50 values comparable to that of their antagonistic IC50 ( Figure S1B) . Importantly, by inhibiting the N-C interaction, the SARDs will not only suppress AR transcriptional activity, but may also inhibit AR binding to chromatin. UT-155 and UT-69 reduce AR expression. Our primary objective was to develop small molecules that would bind to the AR LBD and induce receptor degradation at concentrations comparable to their binding and antagonistic concentrations. We evaluated the effect of UT-155 and UT-69 on AR protein levels via Western blot using N-terminus reactive AR antibody (AR-N20). LNCaP cells were treated with UT-155 and UT-69 in the presence of 0.1 nM R1881. Both UT-155 and UT-69, but not bicalutamide, reduced the AR expression ( Figure 1E ).
Competitive antagonism is sufficient for UT-69, but not for UT-155, to inhibit AR function. UT-69
and UT-155 both compete for binding to the LBD and also reduce AR protein levels at 24 hours comparable to the observed decrease in transcriptional activity. To determine whether the reduction in expression was required to inhibit AR activity or whether the competitive displacement of androgen from the LBD is sufficient to inhibit transcriptional activity, we evaluated the effect of the SARDs on the pre-mRNA of NDRG1 and MT2A genes that are rapidly
Research. induced by hormones (32). We hypothesized that if SARDs act exclusively by reducing AR levels, they will be unable to inhibit the induction of pre-mRNA at 1 or 2 hours as expression of AR is not reduced at this time point. Treatment of LNCaP cells with 0.1 nM R1881 increased the premRNA of both NDRG1 and MT2A by 1 hour and the increase was sustained at 2 and 24 hours (Figure 2A) . Both compounds blocked the expression of the pre-mRNA and the mRNA at 24 hours. While UT-155 failed to inhibit the R1881-dependent increase in the pre-mRNAs observed at 1 and 2 hours, UT-69 inhibited the increase even at early time points. These results indicate that while competitive antagonism through AR LBD is sufficient for the function of UT-69, degradation is necessary for UT-155. These results indicate that UT-155 is a true degrader that requires degradation to elicit its effect and competitive binding to the LBD may not have functional significance.
The distinction in the regulation of early genes between UT-69 and UT-155 provides additional information on the effect of these SARDs on AR N-C interaction. UT-155's inability to inhibit the expression of R1881-induced NDRG-1 and MT2A pre-mRNAs at 1 and 2 hours, the time points at which degradation could not be observed, suggests that UT-155 blocks the N-C interaction only as a consequence of AR degradation. On the other hand, UT-69's effect on R1881-induced NDRG1 and MT2A pre-mRNAs suggests that UT-69 may not require degradation to block the androgen-induced N-C interaction.
Enzalutamide has been reported to prevent binding of AR to chromatin. Thus we asked whether the compounds could block R1881-mediated binding to chromatin, LNCaP cells were pre-treated with UT-155 or UT-69 for 30 minutes and then with 0.1 nM R1881 for 2 hours. Two and a half
Research. hours after the treatment, the cells were fixed to cross-link the protein to DNA. The AR was then immunoprecipitated and recruitment to the PSA enhancer was quantified by real time PCR. While UT-69 inhibited the recruitment of the AR to the ARE on the PSA enhancer, in concordance with the pre-mRNA data, UT-155 failed to inhibit the recruitment of the AR to the ARE on the PSA enhancer ( Figure 2B) . Positive control enzalutamide inhibited the recruitment of AR to PSA enhancer ( Figure 2B) . The experiments shown in the panels were performed at different times and hence the fold recruitment of AR in R1881-treated samples is somewhat different between them.
Although UT-155 can compete with agonist to bind to the purified hormone binding domain ( Figure 1A) , it is possible that the enhanced stability of agonist binding in the full length receptor due to N-C interactions (33,34) is sufficient to prevent most of the binding of UT-155 to the LBD of the full length receptor. Figure 1E showed down-regulation of the AR, which likely is through enhanced degradation, there are a number of alternative possibilities including altered transcription and/or reduced translation. Figure 3A shows that neither compound reduces expression of AR mRNA although expression of FKBP5 is reduced as expected. Figure 3B shows that both compounds reduce AR expression much better than galeterone in LNCaP cells.
SARDs degrade the AR: Although
Quantification of the blots (values expressed under the lanes) indicates that although over 50% of the receptor was degraded at 100 nM, a complete degradation could be observed at 1 µM. UT-155 also reduces AR expression in AD1 cells ( Figure 3C ).
Since the AR N-C interaction does not take place in the absence of agonist ligands, the effect of UT-69 on AR protein levels in cells grown in stripped serum was determined. As shown in Selectivity of AR down-regulation was extensively tested using a range of readouts. First, the effect of UT-155 on the protein level of closely related receptors, PR and estrogen receptor (ER) was tested in T47D breast cancer cells. Although UT-155 blocked PR-dependent transactivation (Figure 1) , it had no effect on PR or ER protein levels in T47D cells ( Figure 3D ). The effect of UT-155 on glucocorticoid receptor (GR) protein levels was tested in PC-3 cells transiently transfected with an expression construct. While UT-155 inhibited the AR protein under similar conditions, it had no effect on GR ( Figure S2A) . Second, the effect of UT-155 on the fluorescence signal emitted by GFP-AR, GFP, or GFP-ANGPTL4 (kind gift from Dr. Lawrence M. Pfeffer, University of Tennessee, TN), a protein that has no homology to nuclear receptors, was tested in Previous studies have shown that molecules that bind to the NTD region are associated with the AF-1 domain that resides between amino acids 141-486 in the NTD region (27).
As a first-step, we evaluated the binding of UT-155 to AF-1 (amino acids 141-486) using steadystate fluorescence emission spectroscopy. There are two tryptophan residues and up to 12 tyrosine residues in the AF-1 domain, providing an opportunity to study the folding properties of this domain using intrinsic steady-state fluorescence emission spectra. Excitation at 287 nm excites both tyrosine and tryptophan residues (44) . This method has been validated as a small molecule binding assay and was used to determine binding of small molecules to human serum albumin (45) and proteins in saliva (46) . To measure the interaction of the individual compounds, steady-state fluorescence was measured in the presence of a dose response of UT-155 and the AF-1 protein.
Research. In the first experiment, UT-155 or enzalutamide (500 μM) was dissolved in deuterated D6DMSO
and was incubated alone or mixed with 5 μM GST-AF-1 or GST and the binding of the molecules to the protein was determined by NMR. While UT-155 alone or in combination with GST exhibited sharp peaks revealing the ligand present in the free state, UT-155 in combination with GST-AF-1 provided broad, diffused, and shorter ligand peaks ( Figure 5B ; peaks in box) revealing that UT-155 has affinity for AF-1. Alternatively, the negative control enzalutamide known to bind to the LBD failed to exhibit a shorter and broader peak in the presence of AF-1 revealing no affinity for AF-1. This result confirms that the UT-155, but not enzalutamide, binds to the AF-1 domain. To further confirm the NMR results, we performed WaterLOGSY with UT-155 alone or in combination with AF-1. While the UT-155 alone gave a flat signal, UT-155 in combination with AF-1 provided a negative signal, characteristic of binding to the protein ( Figure 5C ).
To determine the precise location within the AF-1 region where UT-155 binds (since the AF-1 region is between 141 and 486 amino acids), smaller fragments of AF-1 were produced and purified ( Figure 5D ). UT-155 was incubated alone or in combination with GST, GST-AF-1 or with the various fragments of the AF-1 region and 1 H NMR profiles were obtained. Similar to the 
determine the domain that is important for UT-155's function, we utilized multiple experimental approaches, including site-directed mutagenesis and synthesis of (R)-UT-155.
Molecular modeling was performed to determine the amino acids in the AR-LBD with which UT-155 interacted. UT-155 forms hydrogen bonds with Q711, R752, N705, and L704 ( Figure 6A ).
These sites were mutated and a transactivation assay was performed. Mutating these amino acids individually compromised the ability of R1881 to activate the AR. While the EC50 of R1881 for the wildtype AR was 0.11 nM, the EC50 for the mutant ARs was 7. UT-155 has a chiral center and the active form at the AR LBD is the S-isomer. We synthesized an R-isomer (UT-123 or (R)-UT-155), which is expected to be a weaker LBD binder than the Sisomer. Radioligand binding assay showed that while the S-isomer bound to the AR LBD with a Ki of 267 nM, the R-isomer failed to bind to the AR LBD until 10,000 nM ( Figure 6B) . We tested the effect of (R)-UT-155 on R1881-induced AR transactivation and AR expression. 
23 needed for the antagonistic and degradation effects of UT-155. Since (R)-UT-155 failed to bind to the LBD yet retained its capacity to induce degradation resulting in loss of activity, we speculated that it exclusively binds to the AF-1 domain. We performed an NMR experiment to determine its binding to the AF-1. As expected (R)-UT-155 bound to the AF-1 domain (Figure 6C) 
UT-155 inhibits growth of AR-SV-dependent prostate cancer xenografts. Consistent with the anti-
proliferative effects in vitro, UT-155 significantly inhibited the growth of 22RV1 xenograft by 53%, while, as expected, enzalutamide had no effect on the growth of the 22RV1 tumors ( Figure   7D ). Tumor weights and PSA and the expression of AR and AR-SV were significantly lower in UT-155-treated animals ( Figure 7D ).
In the measurement of drug concentration in the tumors to determine the drug exposure, UT-155 was extracted from tumors and was detected by mass spectrometry. UT-155 accumulated in the tumors and the concentration of 562 nM was above its IC50 concentration ( Figure S8F ).
Pr-3001 is a patient-derived xenograft (PDX) developed using a specimen from an aggressively displays distinct properties. Although UT-155 competes for binding of agonist when measured using a purified LBD, it fails to block the initial induction of transcription (Figure 2) . This is not due to intrinsic agonist activity of the compound because treatment with UT-155 alone yields activity comparable to UT-69 alone (Figure 2A, 1 hour) . The pre-mRNA data suggest that UT-155 may not bind to the LBD in native full-length conformation or may bind transiently enough (faster off-rate) to not have an impact. The agonist-induced N-C interaction is known to slow the off-rate of agonists (33). However, similar to UT-69, UT-155 induces degradation of AR, and thus at 24 hours AR activity is eliminated. Remarkably, these compounds inhibit activity and cause degradation not only of AR and its point mutants, but also induce degradation of AR-SVs. This finding raised the question of whether the compounds also bound to the NTD since the AR-SVs lack the LBD.
Due to the lack of a radioligand competitive binding assay, we acknowledge that the bar to demonstrate the binding to AF-1 is much higher. Hence, we used multiple independent biophysical methods including fluorescence polarization assay, Biacore SPR, and NMR using the AF-1 domain purified proteins. We also used molecular analytical methods such as Western blots that measure the degradation of the AR-SVs that lack LBD, in order to demonstrate the interaction with AF-1. All assays demonstrated a direct interaction, although the concentrations of components needed to detect an interaction differed due to technical limitations and the sensitivities of the techniques. 
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It should be noted that although UT-155 is more potent than enzalutamide by a log unit in vitro, it has to be administered at a much higher dose in vivo than enzalutamide ( Figure 7D) . UT-155 is a first-generation molecule in our library with sub-optimal PK properties. Lead optimization is currently being performed to obtain molecules with optimum PK properties, while retaining the desired degradation properties. Secondly, enzalutamide's poor solubility precluded the use of a dose comparable to that of UT-155. While degradation and AF-1 binding will be the primary and secondary lead optimization criteria, importance will also be given to obtaining an orally bioavailable drug with an optimum PK profile. There is an urgent need to develop novel therapeutic approaches for men with advanced prostate cancer that are not responsive or become resistant to currently used agents. Rapid and sustained
Research. 
